Innovating new treatments for solid tumors
A2 Bio proprietary Tmod™ platform has the ability to absolutely distinguish tumor from normal cells
This is accomplished by integrating multiple signals, overcoming the limits of conventional single-target therapies and by exploiting common, specific gene losses only found in tumor cells
Addressing the fundamental challenge that limits the effectiveness of solid tumor treatment: absolutely distinguishing between tumor and normal cells
Novel.
Precise.
Disruptive.
OUR SCIENCE
The Tmod™ precision-targeting cell therapy platform aims the powerful armaments of immune cells at tumors, while protecting normal cells. A2 Bio has a first-mover advantage in exploiting the loss of genetic material in cancer cells.
Modular.
Flexible.
Expansive.
OUR PIPELINE
Modular and flexible, our platform is designed to enable a broad pipeline of both autologous and allogeneic cell products that access a large array of unexploited therapeutic targets, including targets previously constrained by toxicity.
Pioneering.
Experienced.
Focused.
OUR TEAM
Led by a management team with over 90 years of combined experience in cell therapy and biotechnology, A2 Bio is guided by our science and relentless focus to bring forward bold solutions that alter the course of cancer treatment.
The future of solid tumor therapy utilizes engineered cells to short-circuit immune controls and overpower cancer cells
Well Positioned to Deliver:
- Novel approach that can distinguish tumor from normal cells
- Modular platform enables extensive pipeline generation
- In-house cGMP autologous & allogeneic manufacturing capability
News & Events
November 9, 2024
A2 Bio Highlights Progress of Tmod(TM) CAR T-Cell Clinical Programs during 2024 Annual Meeting of the Society for Immunotherapy of Cancer
October 4, 2024
A2 Bio to Present Safety and Biomarker Data from EVEREST-1 Trial during 2024 Annual Meeting of the Society for Immunotherapy of Cancer
May 29, 2024
A2 Bio Highlights Progress of CAR T-Cell Clinical Programs in Three Poster Presentations during the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting